What is it and what does it include?
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's. This is a 16-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group design study in 146 male and female subjects 50 years or older with mild to moderate Alzheimers disease (AD). Participants received GSK239512 or placebo before randomization, and a weekly review of safety, tolerability, and cognitive performance measures.
How can I use this dataset to advance my research?
This dataset is ideal if:
- you’re investigating the effects GSK239512 and placebo on episodic memory in patients with mild to moderate AD or other cognitive domains.
Has this dataset helped researchers understand Alzheimer’s and other dementias better?
Of course!
- Placebo, H3 Receptor Antagonist, GSK239512, Monotherapy, Mild-to-Moderate Alzheimer’s Disease:
In 2014, researchers showed improved episodic memory in patients with mild to moderate AD GSK239512, at doses up to 80µg/day. However, no improvements were observed on executive function/working memory or other domains of cognition. No changes were observed on any of the clinical measures included as secondary endpoints (including ADAS-Cog) indicating that GSK239512 failed to show benefit in this population. GSK239512 had an acceptable safety and tolerability profile. These findings suggest that H3 antagonists may, at most, have modest and selective effects on cognitive function in patients with mild-to-moderate AD. 2014 – DOI: 10.2174/1567205010666131212110148